UY33455A - Tableta con núcleo recubierto de liberación controlada - Google Patents

Tableta con núcleo recubierto de liberación controlada

Info

Publication number
UY33455A
UY33455A UY0001033455A UY33455A UY33455A UY 33455 A UY33455 A UY 33455A UY 0001033455 A UY0001033455 A UY 0001033455A UY 33455 A UY33455 A UY 33455A UY 33455 A UY33455 A UY 33455A
Authority
UY
Uruguay
Prior art keywords
cyano
methyl
inner core
tablet
thiazolecarboxylic acid
Prior art date
Application number
UY0001033455A
Other languages
English (en)
Inventor
Fujinaga Kentaro
Maruo Susumu
Nakamura Hideaki
Sunagawa Kenji
Mochizuki Tsutomu
Kageyama Michiharu
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of UY33455A publication Critical patent/UY33455A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a una tableta de liberación controlada que contiene un núcleo interno y una porción de capa externa que cubre el núcleo interno, la cual puede mantener la concentración de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico en la sangre a un cierto nivel o superior durante un largo período de tiempo, donde el núcleo interno contiene ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico, y la porción de capa externa contiene ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico y un polímero hidrosoluble formador de gel.
UY0001033455A 2010-06-16 2011-06-15 Tableta con núcleo recubierto de liberación controlada UY33455A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010137323 2010-06-16
JP2010137322 2010-06-16

Publications (1)

Publication Number Publication Date
UY33455A true UY33455A (es) 2012-01-31

Family

ID=45348267

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033455A UY33455A (es) 2010-06-16 2011-06-15 Tableta con núcleo recubierto de liberación controlada

Country Status (9)

Country Link
US (1) US8968779B2 (es)
EP (1) EP2594269A4 (es)
JP (1) JP5669837B2 (es)
AR (1) AR081935A1 (es)
CA (1) CA2802831C (es)
MX (1) MX339452B (es)
TW (1) TW201206502A (es)
UY (1) UY33455A (es)
WO (1) WO2011158870A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579037A (zh) 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
JP7377782B2 (ja) 2019-09-04 2023-11-10 信越化学工業株式会社 フィルム成形用組成物及びフィルム
JP2021104974A (ja) * 2019-12-26 2021-07-26 東和薬品株式会社 フェブキソスタット製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6136982A (en) 1999-01-22 2000-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis of 3-amino-2-chloro-4-methylpyridine from acetone and ethyl cyanoacetate
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP4817562B2 (ja) * 2001-09-26 2011-11-16 東和薬品株式会社 長時間持続型ニフエジピン有核錠
JP5105684B2 (ja) * 2002-03-15 2012-12-26 大塚製薬株式会社 持続性医薬製剤
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
AU2003220909B2 (en) * 2002-03-28 2008-09-18 Teijin Limited Solid preparation containing single crystal form
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US9028867B2 (en) 2005-08-18 2015-05-12 Teijin Pharma Limited Formulation having accurate dose-dividing function
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
SG184754A1 (en) 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
US20100172988A1 (en) 2006-01-10 2010-07-08 Kissei Pharmaceutical Co., Ltd. Sustained release preparation and method for production thereof
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
JP5545952B2 (ja) 2007-08-31 2014-07-09 第一三共株式会社 徐放性製剤及びその製造方法
US20100316711A1 (en) 2007-10-25 2010-12-16 Bayer Yakuhin ,Ltd. Nifedipine containing opress coated tablet and method of preparing same
JP5753082B2 (ja) * 2009-06-26 2015-07-22 帝人ファーマ株式会社 高血圧症または正常高値血圧症の治療薬
CN101671315B (zh) * 2009-08-19 2011-06-22 何广卫 非布索坦的新晶型及其制备方法
CN101658505A (zh) 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
PE20130574A1 (es) * 2010-06-16 2013-06-01 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Also Published As

Publication number Publication date
EP2594269A1 (en) 2013-05-22
US20130089609A1 (en) 2013-04-11
WO2011158870A1 (ja) 2011-12-22
TW201206502A (en) 2012-02-16
MX339452B (es) 2016-05-27
AR081935A1 (es) 2012-10-31
JP5669837B2 (ja) 2015-02-18
MX2012014437A (es) 2013-02-26
JPWO2011158870A1 (ja) 2013-08-19
CA2802831C (en) 2018-11-20
CA2802831A1 (en) 2011-12-22
EP2594269A4 (en) 2013-12-04
US8968779B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
CL2015003185A1 (es) Aparato para la electroobtención o electrorefinación
BR112012000934A2 (pt) cassetes e métodos de utilizacao destes
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
CL2013001316A1 (es) Composicion que comprende micro-organismo probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
BR112013013414A2 (pt) dispositivos de coleta de sangue contendo agente de estabilização de sangue
BRPI1014919A2 (pt) calçado impermeável e transpirante.
BRPI0915147A2 (pt) retentor, mancal de esfera com sulco profundo e mancal com vedação
CL2009000299A1 (es) Sistema optico y procedimiento para detectar la presencia de un elemento biologico vivo; sensor biometrico de identificador de personas.
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
BRPI1009411A2 (pt) preparação externa contendo um agente analgésico/antiinflamatório
BRPI0821720A2 (pt) Aplicação de líquidos iônicos, magnéticos como agente de extração
FR2963357B1 (fr) Materiau photoluminescent contenant de l'ion d'argent
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
UY33455A (es) Tableta con núcleo recubierto de liberación controlada
AR086395A1 (es) Envase para el tratamiento de patologias
CL2014003055A1 (es) Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica.
EA201390090A1 (ru) Дезинфицирующий и антисептический препарат, имеющий сниженное содержание йода
BR112012019626A2 (pt) estrutura de plantio e métodos.
BRPI0922246A2 (pt) copolímero contendo blocos de construção ácida e vários tipos de blocos de construção de poliéter.
EA201270581A1 (ru) Фармацевтические композиции севеламера
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
IT1401736B1 (it) Dispositivo di perforazione per l'esecuzione di diaframmi e relativo metodo.
IT1401350B1 (it) Veicolo - ambulanza per il trasporto di pazienti, feriti e simili
IT1402427B1 (it) Metodo automatico di misura ed elaborazione della pressione sanguigna.
SMT201300027B (it) Impianto e procedimento per la procuzione di una soluzione attivata elettrochimicamente

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807